American Society of Retina Specialists Meeting

American Society of Retina Specialists Meeting

August 11, 2014
1 min read

Triamcinolone, bevacizumab yield similar VA outcomes in cataract patients with DME

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

SAN DIEGO — No significant difference in best corrected visual acuity was seen when patients with diabetic macular edema at the time of cataract surgery were given either triamcinolone or bevacizumab, according to a speaker here.

Salmaan Al-Qureshi

“The poorest visual outcomes are seen in those with diabetic macular edema at the time of surgery,” said Salmaan Al-Qureshi, MBBS, FRANZCO, who presented 6-month results from the DiMECAT trial at the American Society of Retina Specialists annual meeting. “Despite the advances in treatment, there is very little evidence regarding the use of anti-VEGF or triamcinolone in cataract surgery.”

Thirty patients have reached the 6-month follow-up in the prospective, masked clinical trial of 46 patients with diabetic macular edema at the time of cataract surgery. Patients were randomly assigned to receive either 4 mg triamcinolone (Triesence, Alcon) or 1.25 mg bevacizumab (Avastin, Genentech).

Al-Qureshi and colleagues found both groups had an overall increase in BCVA, with the triamcinolone group trending toward a greater gain and better central macular thickness.

There was a statistically significant difference in the number of retreatments between the two groups, with the triamcinolone group needing a mean of 0.19 retreatments and the bevacizumab group requiring a mean of 1.93 retreatments at 6 months.

“There are few studies of the outcome of cataract surgery with either anti-VEGF or [intravitreal triamcinolone] in patients with preexisting DME,” al-Qureshi said.

Reduction in central macular thickness was sustained in the triamcinolone group, whereas central macular thickness tended to increase in the bevacizumab group.

Disclosure: Al-Qureshi has no relevant financial disclosures.